欧洲黑色素瘤的疾病经济负担——已发表文献的系统综述
该系统综述基于PubMed并按PRISMA清单检索欧洲黑色素瘤疾病经济负担(COI)研究,将费用统一换算为欧元并调整至2012年参考年,按购买力平价调整后进行国家间排名。结果显示晚期黑色素瘤治疗费用从意大利的2972欧元到瑞典的17408欧元,I–IV期直接费用从瑞典的923欧元到丹麦的9829欧元。作者指出所纳入国家皮肤癌治疗费用中等偏高,并预期随着新药获批,黑色素瘤治疗费用近年可能上升,预防项目具有较高成本效益甚至节省成本的潜力。
要点
- 晚期黑色素瘤治疗费用按购买力平价调整后为意大利2972欧元至瑞典17408欧元。
- I–IV期黑色素瘤直接费用为瑞典923欧元至丹麦9829欧元。
- 死亡成本为瑞典3511欧元至英格兰20408欧元,疾病成本为瑞典103欧元至英格兰4550欧元。
核心结论
- 所纳入国家的皮肤癌治疗费用中等偏高,且因新药在欧洲获批,近年黑色素瘤治疗费用可能上升,预防项目具有较高成本效益甚至节省成本的潜力。
研究设计与样本
- 系统综述,在PubMed按PRISMA清单进行文献检索,费用统一换算为欧元并调整至2012年参考年,按购买力平价调整后进行国家排名。
主要发现
- 聚焦III–IV期黑色素瘤的研究均包含住院、临终关怀和门诊治疗信息,治疗费用按购买力平价调整后为意大利2972欧元至瑞典17408欧元。
- 多数I–IV期黑色素瘤研究包含住院、门诊治疗和全科医生就诊费用,直接费用为瑞典923欧元至丹麦9829欧元。
- 三篇文章包含间接费用信息,死亡成本为瑞典3511欧元至英格兰20408欧元,疾病成本为瑞典103欧元至英格兰4550欧元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Malignant melanoma accounts for the vast majority of skin cancer deaths. Primary prevention is used to increase knowledge about skin cancer and set incentives for a change in behaviour, which leads to a decrease in cases. Primary prevention may be cost-effective or even cost saving. Cost-of-illness (COI) studies provide information on such potential savings. The purpose of this study is to give an overview on COI studies in European countries and to compare the COI in total and by cost categories. The results can be used to model potential cost savings from prevention. We conducted a systematic literature research in PubMed using the PRISMA checklist. All costs were converted into Euro and adjusted for the reference year 2012. For the ranking of countries according to their COI, all costs were adjusted for the purchasing power parity. All studies focusing on stage III-IV melanoma include information on hospital, hospice, and outpatient treatment. Costs for the treatment of advanced melanoma range between € 2972 in Italy and € 17 408 in Sweden after adjusting for purchasing power parity. Most studies on stage I-IV melanoma include costs of hospitalization, outpatient treatment and general practitioner consultation. Direct costs range from € 923 in Sweden to € 9829 in Denmark. Three articles also include information on indirect costs. Mortality costs vary between € 3511 in Sweden and € 20 408 in England, morbidity costs between € 103 in Sweden and € 4550 in England. We showed that costs for the treatment of skin cancer are moderately high in the included countries. Since after publication of the articles new costly drugs were approved in Europe, treatment costs of melanoma in Europe may be expected to have risen in the last few years, which means that there is a high expectable potential for prevention programmes to become cost-effective or even cost saving.
引用
- Krensel M, Schäfer I, Augustin M, et al. Cost-of-illness of melanoma in Europe - a systematic review of the published literature. J Eur Acad Dermatol Venereol. 2019. PMID: 30408246. doi:10.1111/jdv.15315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。